Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Regulator of nonsense transcripts 1 (UPF1) is a highly conserved ATP-dependent RNA helicase that serves as the central engine of the nonsense-mediated mRNA decay (NMD) pathway (UniProt, PMC2991074). It functions as a molecular surveillance factor, identifying and targeting mRNAs with premature termination codons (PTCs) for rapid degradation to prevent the synthesis of truncated, potentially toxic proteins (NCBI Gene, PMC1782376). Beyond its primary role in NMD, UPF1 is involved in various other RNA decay pathways, DNA replication, and telomere maintenance, making it a critical regulator of cellular homeostasis (PMC2663315, Wikipedia). In disease contexts, UPF1 is often dysregulated; its downregulation is linked to several cancers where it acts as a tumor suppressor, while its modulation is being explored as a therapeutic strategy for genetic diseases caused by nonsense mutations (PMC9858311, Creative Biolabs). Pharmacological targeting of UPF1, primarily through small-molecule inhibitors that disrupt its interactions with other NMD factors like SMG5 or SMG7, aims to stabilize beneficial transcripts or enhance the efficacy of read-through therapies (AACR, PMC3518452). However, its essential role in development and genome stability presents significant challenges for therapeutic window and safety (PMC3603218, PMC2663315).
Inhibition of nonsense-mediated mRNA decay (NMD) by disrupting UPF1 interactions with SMG proteins or inhibiting its ATPase/helicase activity (Santa Cruz Biotech, AACR, PMC3518452).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Regulator of nonsense transcripts 1 (UPF1) (UPF1).